Compare UPLD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | IMRN |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 9.4M |
| IPO Year | 2014 | 2016 |
| Metric | UPLD | IMRN |
|---|---|---|
| Price | $3.96 | $0.97 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 67.2K | 38.1K |
| Earning Date | 11-04-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | $16.39 |
| Revenue Next Year | $0.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $0.68 |
| 52 Week High | $6.65 | $2.24 |
| Indicator | UPLD | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 38.44 |
| Support Level | $2.98 | $0.73 |
| Resistance Level | $4.18 | $1.00 |
| Average True Range (ATR) | 0.47 | 0.07 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 85.25 | 26.42 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.